Amphista will be attending and/or presenting at the following conferences. If you would like to meet with us, please email info@amphista.com
AACR-NCI-EORTC International Conference on Molecular Targets & Cancer Therapeutics
Boston, 11-15 October
6th Targeted Protein Degradation Summit
Boston, 30 Oct – 2 Nov
https://amphista.com/wp-content/uploads/2021/03/UPS.jpg
800
1000
ginealach
https://amphista.com/wp-content/uploads/2022/03/Amphista_Logo-300x270-1.png
ginealach2020-10-15 14:36:122021-03-16 17:03:31The rise and rise of TPD? Personal highlights from the 3rd Annual TPD Summit 14-15th October 2020
https://amphista.com/wp-content/uploads/2021/03/Microtiter.jpg
800
1000
ginealach
https://amphista.com/wp-content/uploads/2022/03/Amphista_Logo-300x270-1.png
ginealach2020-10-11 14:32:292021-03-16 17:03:45It’s not rocket science
Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces it has achieved the first milestone in the second active discovery programme under its strategic collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY), triggering a payment for achieving the […]
Amphista Therapeutics Appoints Dr. Giles Brown as Senior Vice President of Chemistry
Highly experienced medicinal chemist joins to further strengthen Amphista’s next generation TPD approach Cambridge, UK, June 26, 2023 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announced that Giles Brown, PhD, has been appointed as Senior Vice President (SVP) of Chemistry with immediate effect. In […]
Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb
CAMBRIDGE, UK, May 4, 2023 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the delivery of the first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb, triggering a payment for achieving the milestone. Nicola Thompson, CEO of Amphista, said, “we are absolutely delighted with […]